Some historians believe that mushrooms may have sprouted several mainstream Christmas traditions.
As Salon recently reported, the concept of Santa may have been inspired by indigenous Siberian and Northern European shamans who traveled around conducting healing ceremonies during the winter solstice using a type of hallucinogenic mushroom called amanita muscaria, or the fly agaric.
What do you think?!
Read more
CU Cancer Center researchers are collaborating on NCI-funded research to understand the effects of psilocybin on the depression and anxiety that people with cancer can feel.
Read more
“One of the most interesting things we’ve learned about the classic psychedelics is that they have a dramatic effect on the way brain systems synchronize, or move and groove together,” said Matthew Johnson, a professor in psychedelics and consciousness at Johns Hopkins Medicine.
“When someone’s on psilocybin, we see an overall increase in connectivity between areas of the brain that don’t normally communicate well,” Johnson said. “You also see the opposite of that – local networks in the brain that normally interact with each other quite a bit suddenly communicate less.”
Read more
Studies over the past several years have shown promise in using psilocybin-assisted therapy to treat psychiatric disorders like depression.
A recent follow-up study by Johns Hopkins Medicine researchers found two doses of the hallucinogenic compound coupled with psychotherapy resulted in large decreases in major depressive disorder symptoms for most of the study’s participants.
New research is hinting at how the hallucinogenic compound may facilitate reduced depression symptoms.
Read more
A new study suggests that SSRI drugs can be used safely with psilocybin to treat depression. Keep reading to learn more.
Read more
Newsweek says: Magic Mushrooms May Be the Biggest Advance in Treating Depression Since Prozac
Read more
COMPASS Pathways, a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, welcomed the topline data shared today from an open-label study of psilocybin therapy for depression in cancer patients.
Within one week of a single administration of COMP360 psilocybin therapy, 50% of participants achieved remission in depression symptoms, which was sustained for the eight week follow-up period.
Read more